2021-11-172021-11-172006-07Akkaya, C. vd. (2006). ''Comparison of efficacy and tolerability of reboxetine and venlafaxine XR in major depression and major depression with anxiety features: An open label study''. Human Psychopharmacology, 21(5), 337-345.0885-62221099-1077https://doi.org/10.1002/hup.770https://onlinelibrary.wiley.com/doi/10.1002/hup.770http://hdl.handle.net/11452/22672Objective The aim of this study was to compare the efficacy and tolerability of reboxetine in the treatment of major depressive disorder (MDD) and MDD with anxiety features to venlafaxine XR. Method Patients with MDD, aging 18 between 65 years, were randomly allocated to two groups receiving either open-label venlafaxine XR capsules (n = 50) or reboxetine tablets (n = 43). Subjects were administered Hamilton Depression Rating Scale (HAM-D) and Hamilton Anxiety Scale (HAM-A) at baseline and 2, 4, 7, 10 weeks after the baseline visit. Results Response rates to antidepressant treatment were significantly higher in the venlafaxine XR group at 10th week. When patients having anxious depression were analysed separately; response rate for anxiety of reboxetine group was significantly higher at 7th week only. Mean number of side effects were significantly higher in reboxetine group. Only one subject in each group was dropped out due to side effect. Conclusion We may suggest that reboxetine is as effective and tolerable as venlafaxine XR in the treatment of MDD and MDD with anxiety features, and it may be considered a treatment option to venlafaxine XR.eninfo:eu-repo/semantics/closedAccessNeurosciences & neurologyPharmacology & pharmacyPsychologyPsychiatryVenlafaxineTreatmentReboxetineDepression with anxiety featuresDepressionAnxietyLifetimeDisordersManagementPredictorsAssociationComorbidityNoradrenalineRelapseFluoxetineDouble-blindTreatment outcomeTime factorsSeverity of Illness indexPsychiatric status rating scalesMorpholinesMiddle agedMaleHumansFollow-up sstudiesFemaleDrug evaluationDrug administration scheduleDepressive disorder, majorDelayed-action preparationsCyclohexanolsAnxietyAntidepressive agentsAgedAdultAdolescentArticle0002396694000072-s2.0-3374695830933734521516856215Clinical neurologyPharmacology & pharmacyPsychiatryPsychologyMorpholines; Reboxetine; Amino AlcoholsVenlafaxineReboxetineXerostomiaVertigoSweatingStatistical significanceSide effectRandomized controlled trialPriority journalOrthostatic hypotensionOpen studyNauseaMuscle spasmMaleMajor depressionMajor clinical studyInsomniaHumanHot flushHeart palpitationHeadacheHamilton scaleHamilton anxiety scaleFlushingFemaleDrug tolerabilityDrug safetyDrug responseDrug efficacyDizzinessControlled studyControlled clinical trialConstipationClinical trialArticleAnxiety disorderAgedAdult